KRAS WT/SOS1 binding kit HTRF®

The KRAS WT/SOS1 binding kit is designed to identify KRAS WT/SOS1 inhibitors.

See more
  • No-wash No-wash
  • All inclusive kit All inclusive kit
  • Accurate pharmacology Accurate pharmacology

The KRAS WT/SOS1 binding kit is designed to identify KRAS WT/SOS1 inhibitors.



A fast and easy way to identify new inhibitors of KRAS WT / SOS1 protein interactions.

KRAS is a small GTPase implicated in various biological processes, such as cell proliferation, cell survival, and cell metabolism. This proto-oncogene is well known to be mutated in many cancer subtypes, inducing an uncontrolled proliferation and cell metabolism modifications. It thereby contributes to the Warburg effect in cancer cells. Like the majority of small GTPase, KRAS binds to GDP in its inactive form or binds to GTP to switch into the active form. KRAS G12C is one of the most commonly represented mutant forms in cancer, which leads to a permanently active state of KRAS. The Ras guanine nucleotide exchange factor, also called SOS1, is a GEF protein promoting the active form of KRAS. The upregulation of the KRAS / SOS1 interaction leads to cancer phenotypes.



KRAS WT/SOS1 inhibitor screening

Various compounds known to be KRAS or SOS1 inhibitors were added to the assay. BAY-293, BI-3406, BI-2852, and MRTX-1257 display the right potency and pharmacological ranking, in good correlation with the literature. ARS-1620 and AMG-510, two KRAS G12C selective compounds, had no effect on the assay, confirming that the KRAS WT/SOS1 binding kit is specific to the KRAS WT form.

Validation of the HTRF KRAS WT/SOS1 binding kit with inhibitors

Competitive or non competitive nucleotide screening

The two nucleotides GDP and ATP were added to the assay. GDP, a GTP competitor which is well known to bind KRAS WT, displays the right potency, in good correlation with the literature. ATP, a non GTP competitive nucleotide, had no effect on the assay, confirming the specificity of the kit in detecting GTP competitors or KRAS WT / SOS1 inhibitors.

Validation with competitive or non-competitive nucleotides

Best practices for pharmacological characterization of PPI inhibitors

Easy pharmacological characterization of PPI modulators. - Technical Notes

HTRF assays handle low- to high affinity protein-protein interactions

Deciphering low- and high affinity interactions - Application Notes

Nuclear receptor ligand identification with HTRF

Monitoring nuclear receptor binding with HTRF assays - Application Notes

HTRF addresses large protein-protein interaction complexes

Challenge large complexes with HTRF assays - Application Notes

HTRF PPI your dream assay served on a plate

Sandwiches aren't just for eating - Infographics

A brief history of Protein-Protein Interactions

How well do you know PPI? - Infographics

Virology research solutions using HTRF Protein-Protein Interaction assays

See how peer researchers challenge the viral life cycle with PPI assays - Application Notes


64KRASWTPEG-64KRASWTPEH - Product Insert

KRAS GTP competitors and KRAS/SOS1 inhibitors screening with new HTRF biochemical-based assays

Screening for KRAS competitors and inhibitors with HTRF technology - Application Notes

Plate Reader Requirement

Choosing the right microplate reader ensures you’ll get an optimal readout. Discover our high performance reader, or verify if your lab equipment is going to be compatible with this detection technology.

Let's find your reader